# Efficacy and Safety of LT3001 on Treating the Acute Ischemic Stroke

> **NCT05686642** · PHASE2 · RECRUITING · sponsor: **Shanghai Pharmaceuticals Holding Co., Ltd** · enrollment: 300 (estimated)

## Conditions studied

- Acute Ischemic Stroke

## Interventions

- **DRUG:** LT3001 Drug:high dose
- **DRUG:** Placebo
- **DRUG:** LT3001 Drug:low dose

## Key facts

- **NCT ID:** NCT05686642
- **Lead sponsor:** Shanghai Pharmaceuticals Holding Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-04-06
- **Primary completion:** 2026-12-10
- **Final completion:** 2026-12-12
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2026-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05686642

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05686642, "Efficacy and Safety of LT3001 on Treating the Acute Ischemic Stroke". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05686642. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*